AZD-2461

1174043-16-3

C22H22FN3O3

DMSO : >= 100 mg/mL (252.89 mM)

Epigenetics; Cell Cycle/DNA Damage

AZD-2461 is a potent PARP inhibitor, with IC₅₀s of 5 nM, 2 nM and 200 nM for PARP1, PARP2 and PARP3, respectively. IC50 & Target: IC50: 5 nM (PARP1), 2 nM (PARP2), 200 nM (PARP3)^[1] In Vitro: AZD-2461 is a potent PARP inhibitor, with IC₅₀s of 5 nM, 2 nM and 200 nM for PARP1, PARP2 and PARP3, respectively. AZD-2461 (500 nM) shows inhibitory activity against DNA single-strand break repair in human A459 cells. AZD-2461 cuases resistance and high P-gp expression levels in BRCA2-deficient mouse breast cancer line KB2P3.4^[1]. AZD-2461 is cytotoxic to BT-20 cells (5-50 uM), increases the proportions of S- and G2-phase BT-20 cells (5-20 uM), and weakly affects the progression of cell cycle in SKBr-3 cells (5-20 uM)^[2]. In Vivo: AZD-2461 (10 mg/kg, p.o.) enhances the antitumor activity of temozolomide in a mouse colorectal xenograft and exhibits low effect on mouse bone marrow cells. However, the increased bone marrow tolerability of AZD-2461 is not seen in rat models^[1]. AZD-2461 (0.5% v/w HPMC, p.o.) increases the survival of mice bearing KB1P tumors after short-term treatment, and long-term treatment is well tolerated, but can not lead to tumor eradication^[3].